申请人:Grainger David J.
公开号:US20100016286A1
公开(公告)日:2010-01-21
The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(r-methylcyclohexyl-carbonylamino)-caprolactam: wherein z is 1, 2, 3 or 4; A is —CO— or —SO2-; Q is linear or branched alkyl, alkenyl, alkynyl, alkoxy, oxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, haloalkyl, aryl or substituted aryl; T
1
and T
2
together constitute a cycloalkyl, cycloalkenyl or polycycloalkyl radical composed of n additional carbon atoms, where n is between 2 and 7; and each hydrogen atom bonded to the carbon atoms in the ring generated by T
1
and T
2
may be independently be substituted by a group R
1
, where R
1
is independently selected from an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms; or each R
1
is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical.
本发明提供了一般式(I)的化合物、药物组合物及其盐的用途,用于制备治疗炎症性疾病的药物,但不包括(S)-3-(r-甲基环己烷甲酰氨基)-己内酯:其中,z为1、2、3或4;A为—CO—或—SO2-;Q为线性或支链烷基、烯基、炔基、烷氧基、氧烷基、氨基烷基、烷基氨基、烷基氨基烷基、卤代烷基、芳基或取代芳基;T1和T2共同构成由n个额外碳原子组成的环状烷基、环状烯基或多环烷基基团,其中n介于2和7之间;并且,T1和T2生成的环上的每个碳原子上的氢原子可以独立地被取代为R1基团,其中R1独立地选自具有1到20个碳原子的烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基或烷基氨基基团;或每个R1独立地选自氟、氯、溴、碘、羟基、氧烷基、氨基、氨基烷基或氨基二烷基基团。